sb 202190 has been researched along with Encephalitozoonosis in 1 studies
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase
Encephalitozoonosis: Infection with FUNGI of the genus ENCEPHALITOZOON. Lesions commonly occur in the BRAIN and KIDNEY tubules. Other sites of infection in MAMMALS are the LIVER; ADRENAL GLANDS; OPTIC NERVES; RETINA; and MYOCARDIUM.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wei, S | 1 |
| Daniel, BJ | 1 |
| Brumlik, MJ | 1 |
| Burow, ME | 1 |
| Zou, W | 1 |
| Khan, IA | 1 |
| Wadsworth, S | 1 |
| Siekierka, J | 1 |
| Curiel, TJ | 1 |
1 other study available for sb 202190 and Encephalitozoonosis
| Article | Year |
|---|---|
Drugs designed to inhibit human p38 mitogen-activated protein kinase activation treat Toxoplasma gondii and Encephalitozoon cuniculi infection.
Topics: Animals; Antiprotozoal Agents; CD8 Antigens; Dose-Response Relationship, Drug; Drug Design; Drug Syn | 2007 |